Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
F008
- Development stage
- Phase 1
- Lead developer
- Shandong New Time Pharmaceutical
- Administration
- Intravenous
01
Overview
F008 is an investigational drug currently undergoing a Phase I clinical study to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects. The drug is being developed for the treatment of Acute Ischemic Stroke (AIS) and is administered intravenously. The clinical development is a collaborative effort between West China Hospital of Sichuan University and Shandong New Times Pharmaceutical Co., LTD.
Beyond the preview
Go deeper on F008.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on F008.